Targeted screening tests

Targeted screening tests for detection & prevention of HA-MRSA and S. aureus infections

The BD MAX™ MRSA XT and StaphSR assays allow for detection of patients at risk for nasal colonisation with Staphylococcus aureus or MRSA

Overcome the
challenges of SSI
Importance of accurate screening and detection
Choose efficiency

The burden of Surgical Site Infections (SSIs)

  • SSIs are the most common healthcare-associated infections (HAIs) in Europe – the rate of SSIs varies from 0.5% to 10.1%1
  • S. aureus can cause community-acquired and healthcare-acquired infections ranging from skin and soft tissue infections to sepsis and death
  • Patients with an SSI have a 2 to 11 times higher rate of mortality as compared to surgical patients without an SSI2
  • Asymptomatic nasal carriers of S. aureus have a risk of HAI three to six times higher than among non-carriers3-5
  • Most infections in carriers are endogenous infections6
  • The number of surgical-site S. aureus infections acquired in the hospital can be reduced by rapid PCR screening and decolonisation of nasal carriers of S. aureus upon admission7
  • Patients asymptomatically colonised with MRSA are a substantial reservoir for person-to-person spread in the hospital8
  • BD MAX™ MRSA XT detects 11 MREJ genotypes plus mecA drop-out mutants and the mecC gene9
  • BD MAX™ StaphSR detects both S. aureus and MRSA with the same Extended Detection Technology as the BD MAX™ MRSA XT assay10
  • Results for up to 24 patients in just over 2 hours to allow institutions to implement effective infection control procedures, thus avoiding transmission and subsequent infections9,10
  • Fully integrated on the BD MAX™ System with ready to use reagents stored at room temperature on a fully automated platform

BD MAX™ MRSA XT and StaphSR assaysAre part of the BD MAX™ Portfolio of HAI assays